mental health Archives

FDA Program Promises to End Years of Ketamine Shortages for Mental Health Clinics

Phlow Corp. has been selected for the FDA's inaugural Commissioner's National Priority Voucher Pilot Program to manufacture ketamine's active pharmaceutical ingredient domestically.

October 2025 Roundup: What Ketamine Treatment Costs Across the United States

The cost of ketamine therapy continues to evolve. Here's what ketamine treatments cost across the US in October of 2025.

The Psychedelic Pharmaceutical Market Projected to Hit $17B in Next Decade

The global market for these compounds reached $4.75 billion in 2025. Analysts project growth to $16.93 billion by 2034.

A Breakthrough for Depression Treatment: FDA Fast Tracks atai’s Novel Nasal Spray

The FDA has granted Breakthrough Therapy designation to BPL-003, a nasal spray that could transform treatment for patients whose depression resists standard medications.

Gavin Newsom Speeds Psychedelic Research With New Law Backed by Veterans

California Governor Gavin Newsom has signed Assembly Bill 1103, a measure to accelerate the study of psychedelics.

Introducing the Ketamine Industry’s Most Comprehensive Professional Liability Coverage

Most ketamine clinics think their liability insurance their ketamine treatments -- but for most it doesn't. We solved this problem.

Reimagining End of Life Care: Psychedelic Assisted Therapy Enters the Conversation

New research is shining light on psychedelic assisted therapies as a possible tool to enhance quality of life, ease existential distress, and contain costs.

Psychedelics Affect Far More Brain Cells Than Scientists Believed

Scientists at the University of Michigan have upended a foundational assumption about how psychedelic medicine works in the brain.

Beyond Traditional Training: How Psychedelics Are Reshaping Executive Leadership

Dr. Catriona Wallace reveals that 52% of surveyed leaders noted long-term improvements in company leadership attributed to psychedelic use.

IV Ketamine Shows Superior Results Over Nasal Esketamine for Treatment Resistant Depression

A new study shows that IV ketamine delivers more effective relief with treatment resistant depression compared to its nasal counterpart